Objective .T oassess the use of antihypertensive drugs and blood pressure (BP) levels in relation to current guidelines for BP control in patients with chronic renal failure (CRF). Material and methods.Across-sectional survey was carried out in six renal outpatient clinics in Oslo and the surrounding area. The hospital records of all renal patients not yet in need of renal replacement therapy and with serum creatinine ] / 200 m mol/l who attended consultations with nephrologists regularly (at least everythird month) were reviewed. Results.O fthe 351 patients, 97% had hypertension. The majority of patients (96%) were receiving antihypertensive therapy.The average number of antihypertensive drugs being taken was 2.79 / 1.3 (median 3), but it varied with the cause of CRF.The drugs most frequently prescribed as monotherapy were angiotensin-converting enzyme inhibitorso ra ngiotensin II receptor antagonists, which were used by 32%; 51% of patients were using three or more antihypertensive drugs. Loop diuretics were prescribed as monotherapy in 25% of cases and in combination with twoo rm ore other drugs in 87%. Age and serum creatinine levels influenced the choice of antihypertensive therapy. The target BP of B / 130/80 mmHg was obtained in 13% of patients, and lack of optimal BP control was mainly due to systolic hypertension. At otal of 38% of patients had aB Po f B / 140/90 mmHg,w hile 58% failed to achieveasystolic BP of B / 140 mmHg. Conclusion.O ptimal blood pressure control is hard to achieve in patients with CRF,e venw ith specialist care and the use of multiple antihypertensive drugs.
Introduction
Hypertension is the single most important risk factor for progression of diabetic and non-diabetic kidney diseasea nd renal insufficiency[ 1 Á / 3]. Lowering blood pressure per se leadst oo rgan protection, and medication interfering with the renin Á / angiotensin system, i.e. angiotensin II receptor antagonists (ARBs) and angiotensin-converting enzyme inhibitors( ACEIs), confersr enoprotection beyond that of blood pressurel owering [4 Á / 8] .
Death from cardiovascular diseaseinpatientswith chronic renal failure( CRF)i sh igh and greatly exceeds that of the general population [9, 10] . It has thus been argued that risk reduction shouldstart during the early stages of renal insufficiency [11] . In high-risk patients, modulation of risk factors, even within what is considered the normal range, may have agreat impactoncardiovascular morbidity and mortality [11, 12] .
Given the benefit of reduction of blood pressure (BP) in this population, there is consensus regarding the importance of good controlo fB Pi np atients with chronic kidney diseasea nd renal insufficiency. Thus, recentguidelines basedonobservational data [13 Á / 15] advise lowering BP below 130/ 80 mmHg.
Given this background, the aim of this investigation was to assess the use of antihypertensive drugs and BP levels in patientsw ith CRF whoh ad not reached the stage of requiring renal replacement therapy,b ut were receiving regular care at renal units.
Material and methods

Study design
Renal units at six different hospitals in the southern parto fN orway participated in ac ross-sectional surveyb ased on hospital records of patientsw ith CRF with serum creatinine ] / 200 m mol/l. These hospitals cover the referral area for nephrology for / 1.75 million Norwegians, close to 40% of the entire population. The doctorsw ho care for these patientsa re allh ighlyt rained nephrologys pecialists. During a6-month period, two of the authors(M. G. S. and L. K. P. )r eviewed the hospital records of patientsw ho had been indicated as eligible for the study by consultingn ephrologists. Only ambulatory patientsc ouldb ei ncluded, and they had to attend regular consultations at least everyt hird month at the renal unit. Furthermore, theyh ad to have attended ac onsultation within the previous3 Á / 4 months. Patients with acute renal failurewith serum creatininee levation of B / 3months duration, or patientsw ho had previously beend ialyzed or transplanted could not be included. Currentd ialysis was also an exclusion criterion. All patientswho fulfilled the inclusion criteria were includedi nt he study.
Data from the last visit( within the previous 3months)w ere always used. The date of first admission, diagnosis, cardiovascular history(macrovascular disease, i.e. myocardial infarction, stroke, peripheralv ascular diseaseo ra ortic aneurysm)a nd laboratorym easurementsa td ifferent times (including the last visit) were recorded. The drug regimen in use at the last visitb efore the survey was usedf or registration. The classesofa ntihypertensive medication were registered, andf or loop diuretics the dosage was also registered. Fort hose using bumetanide ( B / 5% of patients), the dose was converted to that for furosemide, i.e. 1mgofbumetanide 0 / 40 mg of furosemide. BP measurementsa tt he time of admission to hospital and at the last visit before the present investigation were also entered into the database.P ulse pressure (PP) was calculatedb y subtracting diastolic( D)BP from systolic (S)BP. The mostr ecentm easurements of totalc holesterol, high-density lipoprotein (HDL) cholesterol, triglycerides and glucose available in the hospitalr ecords were noted. Serum creatinine was used as ameasure of kidney function.C reatininec learance couldb e calculatedi nt wo-thirds of the patients using the Cockcroft Á / Gault formula. Recordso fp roteinuria were often lacking and, if they were present, had been obtained using various methodologies and the results were mostly qualitative or semi-quantitative. Therefore these data were notc ollected.
The diagnosis of diabetic nephropathy was based on hospitalrecords, as were the othercauses of CRF. In the majority of patients the diagnosis is made on the basis of clinical assessments, and only in a minority of cases is it basedo nr enal biopsy.T he cause of CRF was categorized as eitherc hronic glomerulonephritis, diabetic nephropathy (types1 and 2), nephrosclerosis and hypertensive renal disease, chronic pyelonephritis and interstitial nephritis, or other( renala myloidosis, adult polycystick idney disease andr enal carcinoma,u nclassified chronic renal disease).
Patients were labelled as hypertensive basedo n hospital records of BP measurementsa ta dmission, use of antihypertensivedrugs or aBPatthe last visit of / 140/90 mmHg. Controlled andu ncontrolled hypertension were defined as aB Pof B / and ] / 130/ 80 mmHg, respectively at the last consultation. The threshold for defining controlled hypertension was also set at B / 140/90 mmHg, and analysed accordingly.
Statistics
All data are presented as mean9 / SD unlesss tated otherwise.F or differences in BP,9 5% CIs are given as well.F or skewed data, the median, Q1 (25% percentile)a nd Q3 (75% percentile) are given. Comparisons were made using the x 2 test, Student's t -test, ANOVA and, for skeweddistributions of data, Wilcoxon'st est andt he Mann Á / Whitney U-test. Simple bivariate relationships were assessed by calculatingS pearman's correlation coefficient. Age and serum creatinine were also categorized in tertiles. The statisticala nalysis was performedu sing SPSS statistical software (version 11.0; SPSS Inc., Cary, NC). Two-tailed p -values 5 / 0.05 were considered statistically significant.
Results
More than 600 hospital records were assessed, and those of 376 Caucasian patientswith CRF whowere not on dialysis and had never previously been transplanted or dialysed were entered into the database.O ft hese, 25 did not fulfil the inclusion criterion of serum creatinine ] / 200 m mol/l at the last visit, and thus data from 351 patientswere analyzed.
The mean time from the first referral for chronic kidney diseasew as 40 months, with aw ide range of 3 Á / 394 months. Some of the patient characteristics are giveni nT ables Ia nd II (patients are categorized accordingt oa ge tertiles in the latter). Age was positively related, althoughweakly,toSBP ( r 0 / 0. 23, p B / 0.001) and PP ( r 0 / 0.25, p B / 0.0001), while an inverse relationship with DBP was observed ( r 0 / ( / 0.14, p 0 / 0.003). Serum creatinine did not differ across the age tertiles at the time of investigation, while estimated creatininec learance( n 0 / 223) showed an inverse relationship with age ( r 0 / ( / 0.40, p B / 0.001).
The major cause of CRF in this population of patientsattending arenal unitregularly was nephrosclerosis, followed by diabetic nephropathy (Table  III) . The aetiology of CRF differedw ith age, with nephrosclerosis being the most prevalent cause in the oldest age group andc hronic glomerulonephritis being most frequenti nt he youngerp opulation (TableIII). Diabetes nephropathy as acause of renal failure did notd iffers ignificantly across the age tertiles. The presence of macrovascular disease increased across the age tertiles (Table II) .
Use of drugs
Multipharmacywas frequent, with amedian of three drugs (2.79 / 1.3) being prescribed, while only 3.9% of patientsw ere notp rescribed any antihypertensive therapy.O verall, the most frequently usedd rugs were loop diuretics, which were used by 65.8% of patients, with an average dose of 1259 / 124 mg (median 80 mg; Q1 Á / Q3 40 Á / 160 mg). Calcium channel blockers( CCBs)w ere used by 60.2% of patients, beta-adrenergicr eceptor blockers( BBs) by 52.8% and ACEIs or ARBs by 45.1%. Otherd rugs, i.e. alpha-receptor blockers, alphamethyldopa, thiazides or moxonidine, were used by 39.0%.ACEIs or ARBs were most frequently useda sm onotherapy, while loopd iuretics were used as monotherapy by 25% of patients( Ta ble IV). None of the patientsi n the current survey used acombination of ACEIs and ARBs.
The use of medication seemedt od iffer across the range of serum creatinine levels, with as ignificant decrease in the use of ACEIs and ARBs with rising creatininelevels, while the use of CCBs and diuretics remained the same (Figure 1 ).L oop diuretics were the most frequently used drugs in the oldest age groups ( p 0 / 0.07). The dosage of loopd iuretics also seemed to be higher in the oldest patients, but this did not reachs tatistical significance ( p 0 / 0.27). There was am arked decrease in the use of ACEIs or ARBs with increasinga ge ( p B / 0.0001), with less than aq uarter of the oldest patients using these classes of drugs. BBs were also more frequently used in the oldest patients ( p 0 / 0.006). Overall use of statins was 48.3%, and did not differ between age groups ( p 0 / 0.77). The causeo fC RF influenced the use of antihypertensived rugs (Figure 2 ), andt his was note xplained by differences in SBP ( p 0 / 0.16), DBP ( p 0 / 0.35) or serum creatinine ( p 0 / 0.58).
BP levels
Overall, there was ahighly significant decrease in BP in the hypertensivep atients after referral to hospital (Figure 3 ). The decrease in SBP was 13 The median changei ns erum creatinine levels for all patients from the time of referral to the time-point of the surveywas ' / 55 m mol/l ( ( / 4to ' / 147 m mol/l). There was aw eak correlation between the changein serum creatinine level andD BP at the referral time ( r 0 / 0.22, p B / 0.001), but there was no corresponding correlation with SBP ( r 0 / 0.14, p 0 / NS).
Those patients whoe xperienced ar ise in serum creatininel evel between the time of referral and the time of the surveyh ad ah igher DBP at the time of referral compared to those with ad ecrease in creatininel evel ( 
Discussion
Close to 97% of our patients with CRF had elevated BP or were being treated with antihypertensive drugs, comparable with the prevalence of hypertension observedi nalarge American study [16] .
This was ah ighlys elected group of patients as they were receiving regular care from nephrologists but, despite an impressive decrease in BP between the referral time and the present survey,B Pc ontrol was not optimal.O nly 13% of patientsh ad BP levelsi na ccordance with current recommendations ( B / 130/80 mmHg), and uncontrolled SBP was the major cause of failuret om eet that target. The proportion of patientsw ho achieved the more conservativeB Pg oal of B / 140/90 mm Hg was 38%, in accordance with other reports [16 Á / 18 ]. This figure is an improvement on what has been achieved among patients with essential hypertension in general practice [19] .
PP has emerged as an important and independent risk factor for cardiovascular disease [20] andh as recently been put forward as amajor determinant of progression of renal diseasea nd renal insufficiency [2] . Some authorsh avet herefore suggested that rather than aiming at good controlofDBP,the focus should be on controlling SBP and PP [2] . In elderly hypertensivesubjects with isolated systolic hypertension, an increase in PP of 10 mmHgc onfers increased risksofcongestive heartfailureand strokeof 32% and2 4%, respectively [21] . The number of patientsinthe presentstudy is too small to enable definite conclusions to be drawn regarding differences in the prevalence of hypertension depending on the aetiology of CRF,a so thers have done [16, 17] . However, we did note ad ifference in the use of antihypertensive drugs depending on aetiology,a st he number of drugs prescribed was higher in patients with diabetic nephropathy or nephrosclerosis compared to those with chronic glomerulonephritis.
Someofthe usual barrierstogood BP control, e.g. access to good healthcare, cannot explain our finding of al ow rateo fo ptimal BP control as specialist hospitalc are was ap rerequisite for entering the study.The majority of ourpatientsrequired multiple antihypertensive drugs: the average numberofdrugs prescribedi nt he presents tudy was higher than that reported in others tudies [17] , but similar to that used in randomized clinical trials [4, 6, 22] . The patients in the present survey had more severe renal impairmentt han those in comparable studies addressing BP control, and our patientsa lso suffered more from macrovascular disease.
Multipharmacy was prevalent, and the majority of patients used two or more drugs. Drugs interfering with the renin Á / angiotensin system were those most frequentlyu sed as monotherapy,b ut they were also prescribedt om ore than half of patientsu sing three or more antihypertensive drugs. Overall, loopd iuretics were the mostf requentlyp rescribed antihypertensive drugs.W hile aq uarter of patientsr eceiving monotherapy used loopd iuretics, the proportion rose to 87% when three or more drugs were prescribed. Furthermore, ah igh proportion of patients used CCBs andBBs.Among younger patients, ACEIs or ARBs were more often preferred,w hich were used in only aminority in the upperage group. The use of diuretics increased in the oldest age group. The frequentc hoice of ACEIs or ARBs is not surprising given the results of recent clinical trials in both diabetic and non-diabetic kidney diseasei ndicating ar enoprotective role of these drugs beyond that whichc an be explained by blood pressure lowering [2,4 Á / 8,22] . Excess volume plays an important role in developing and sustaining hypertension in CRF [23] andtherefore use of loopdiuretics is frequent, as observedinour study.Asthe effectof loop diuretics is dependento nr enal function, the dose should be increased in this patient population, which may lead to improved BP control. Combination therapy with ACEIs and ARBs has been proposed [24 Á / 26],b ut none of the patientsu sed this combination in the presents urvey.A sk idney function declines, the risk of accumulation of ACEIs increases,a nd this is probably the major causef or the decreased usage of ACEIs with advancing renal failure. However, this couldleadtouse of these drug classes being overly restricted in patients who may benefit from the treatment [27, 28] .
CCBs are recommendedi nt he formo fc ombination therapyi nr enal patients [29] . It has been proposed [30, 31] that CCBs mayb ep articularly beneficial in patientsw ith end-stage renal failure with disturbances of calcium Á / phosphatem etabolism. However, am ore likelye xplanation for the frequentu se of CCBs is their safety profile in this setting.
Newerd ata [ 32, 33] suggest that sympathetic overactivity is an important contributort ohypertension in renal failure, and renal patients maytherefore benefit from the use of BBs. Furthermore, a substantial numbero fp atientsi nt he currents urvey were suffering from coronaryh eartd isease, which wouldh avei ncreased the use of BBs.
Based on the strict inclusion criteria we used to select ourp atients, our findings may not be applicable to patientswith creatinine values B / 200 m mol/l, those attending outpatiente xaminationsa tr egular intervals of / 3months or not on aregular basis and patientsattending examinationsbut with consultants other thananephrologist.
Af urther limitation of this study is that it was based on data from hospital charts. We haven o information about compliance with or adherence to the prescribed drug regimens. The BP recordings were all taken in asitting position andinaccordance with good clinical practice, andt hese measurements were the ones the nephrologists based their decisions on. In the majority of cases, the cause of CRF is determined based on clinical assessment rathert han renal biopsy.T his mayl eadt oo verestimation of the incidences of nephrosclerosis andd iabetic nephropathy.H owever, the high numbero fc ases of nephrosclerosis or hypertensive renal diseaset hat were registered in the presentsurvey is in accordance with the increase in prevalence observedi no ther European countries, anda lsoi na greement with reports from the Norwegian registryf or patients enrolled in dialysis treatment or transplantation programmes [34] . Hypertension as ap rimaryc ause of end-stage renal failure has risen from 5% to 28% over the last 20 years, while chronic glomerulonephritis has decreasedf rom 34% to 17% [34] .
This study tookp lace in 2003, the same year in which new guidelines were issued [13 Á / 15].T here seems to be ac onsensus regarding the targetB Pi n patients with nephropathy,d espite the fact that the guidelines are basedo no bservational findings and there is ap aucity of findings from clinical trials. However, in some studies [35] t he renoprotective effect of atargetBPof B / 130/80 mmHg,asopposed to B / 140/90 mmHg,i sn ot supported.
In conclusion,a lthoughh ypertensioni st he single most important risk factor for progression of chronic kidney disease, and am ajor risk factor for cardiovascular disease in renal patients, BP control in this high-risk population is farf rom optimal,d espitet he extensive use of multiple antihypertensive drugs. Randomized controlled studiesd efining the threshold for optimal BP controli np atients with CRF are clearly needed. Based on our observations,w e suggest that ahigher dosage of loop diuretics should be consideredt oi mproveB Pc ontrol in renal patients, and that the use of drugs interfering with the renin Á / angiotensin system shouldb ec arefully scrutinized in these patients.
